{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Qiu Y"],"funding":["U.S. Department of Health and Human Services","University of Wisconsin-Madison","NIGMS NIH HHS"],"pagination":["3857-3868"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11522902"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["4(10)"],"pubmed_abstract":["Targeted protein degradation (TPD) is emerging as a promising therapeutic approach for cancer and other diseases, with an increasing number of programs demonstrating its efficacy in human clinical trials. One notable method for TPD is Proteolysis Targeting Chimeras (PROTACs) that selectively degrade a protein of interest (POI) through E3-ligase induced ubiquitination followed by proteasomal degradation. PROTACs utilize a warhead-linker-ligand architecture to bring the POI (bound to the warhead) and the E3 ligase (bound to the ligand) into proximity. The resulting non-native protein-protein interactions (PPIs) formed between the POI and E3 ligase lead to the formation of a stable ternary complex, enhancing cooperativity for TPD. A significant challenge in PROTAC design is the screening of t"],"journal":["JACS Au"],"pubmed_title":["Non-Markovian Dynamic Models Identify Non-Canonical KRAS-VHL Encounter Complex Conformations for Novel PROTAC Design."],"pmcid":["PMC11522902"],"funding_grant_id":["Hirschfelder Professorship Fund","NIH R35GM148266","Research Forward Fund","R35 GM148266"],"pubmed_authors":["Qiu Y","Huang X","Wiewiora RP","Izaguirre JA","Sherman W","Xu H","Tang W"],"additional_accession":[]},"is_claimable":false,"name":"Non-Markovian Dynamic Models Identify Non-Canonical KRAS-VHL Encounter Complex Conformations for Novel PROTAC Design.","description":"Targeted protein degradation (TPD) is emerging as a promising therapeutic approach for cancer and other diseases, with an increasing number of programs demonstrating its efficacy in human clinical trials. One notable method for TPD is Proteolysis Targeting Chimeras (PROTACs) that selectively degrade a protein of interest (POI) through E3-ligase induced ubiquitination followed by proteasomal degradation. PROTACs utilize a warhead-linker-ligand architecture to bring the POI (bound to the warhead) and the E3 ligase (bound to the ligand) into proximity. The resulting non-native protein-protein interactions (PPIs) formed between the POI and E3 ligase lead to the formation of a stable ternary complex, enhancing cooperativity for TPD. A significant challenge in PROTAC design is the screening of t","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-04-29T23:17:18.179Z","creation":"2025-04-21T21:50:46.996Z"},"accession":"S-EPMC11522902","cross_references":{"pubmed":["39483225"],"doi":["10.1021/jacsau.4c00503"]}}